Topic

Articles

The United Kingdom’s government has emphatically voted against the Prime Minister’s proposed withdrawal deal in the largest defeat the House of Commons has faced in its history. So, what is next for Brexit and, in particular, the pharma industry?

Preparation Urged as Brexit Withdrawal Deal is Denied by UK Parliament

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

As Brexit rapidly approaches, the lack of clarity around the regulatory balance between the regions could lead to a reduction in standards.


Regulatory Divergence: The Burden of Brexit?

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Intellectual challenge, work/life balance, compensation, and an unclear business outlook create uncertainty among European bio/pharma employees.

Apprehension Shapes Employee Satisfaction

Sean Milmo is a freelance writer based in Essex, UK.

This coming year could see a combination of regulatory uncertainty and inactivity for the pharma industry, mainly as a result of Brexit.

A Year of Possible Regulatory Upheaval and Paralysis

The UK Pharma Industry has emphasised the need for the government to avoid a 'no-deal' Brexit in response to the prime minister delaying the deal vote.

UK Pharma Industry Emphasizes Need to Avoid a ‘No-Deal’ Brexit

According to research from staffing firm, Kelly Services, 14% of life science professionals based in the UK may move abroad if Brexit results in negative changes to economic conditions.

Brexit May Cause Exodus of Life Sciences Professionals from UK, Notes Research

Taking stock on the ‘big-ticket’ news items, both good and bad, from the past 12 months.

The Good, The Bad, and The Brexit

EMA’s relocation to Amsterdam and resulting staff losses could severely weaken the agency’s role as a leading medicines regulator.

Relocating EMA: A Far from Ideal Situation

A coalition group from the UK's health sector has called on both the UK and EU to ensure the protection of patients and public health when considering the future relationship of the regions post-Brexit.

Coalition of UK’s Health Sector Request Protection for Public Health Post-Brexit

During CPhI Worldwide in Madrid, Lynne Byers, executive director of NSF International detailed the facts about how Brexit can impact the pharmaceutical industry.

Bio/Pharma and Brexit